Novoeight is a brand name for Antihemophilic Factor (Recombinant), which is a medication used in the treatment and prevention of bleeding episodes in individuals with hemophilia A, a genetic disorder characterized by a deficiency in factor VIII, a protein necessary for blood clotting. Produced through recombinant DNA technology, Novoeight mimics the action of natural factor VIII, thereby helping to control and prevent bleeding. It is administered via injection into a vein, and its dosing can vary based on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient's body weight. Novoeight is designed for use in patients of all ages, offering a critical therapeutic option to manage this chronic bleeding disorder effectively.